Mohammed Farooqui

3.1k total citations
53 papers, 1.6k citations indexed

About

Mohammed Farooqui is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Mohammed Farooqui has authored 53 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Genetics, 31 papers in Pathology and Forensic Medicine and 19 papers in Immunology. Recurrent topics in Mohammed Farooqui's work include Chronic Lymphocytic Leukemia Research (49 papers), Lymphoma Diagnosis and Treatment (31 papers) and Immunodeficiency and Autoimmune Disorders (16 papers). Mohammed Farooqui is often cited by papers focused on Chronic Lymphocytic Leukemia Research (49 papers), Lymphoma Diagnosis and Treatment (31 papers) and Immunodeficiency and Autoimmune Disorders (16 papers). Mohammed Farooqui collaborates with scholars based in United States, Netherlands and India. Mohammed Farooqui's co-authors include Adrian Wiestner, Sarah E. M. Herman, Xin Tian, Janet Valdez, Maryalice Stetler‐Stevenson, Rashida Z. Mustafa, Susan Soto, Constance M. Yuan, Stefania Pittaluga and Irina Marić and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mohammed Farooqui

50 papers receiving 1.6k citations

Peers

Countries citing papers authored by Mohammed Farooqui

Since Specialization

Citations

This map shows the geographic impact of Mohammed Farooqui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed Farooqui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed Farooqui more than expected).

Fields of papers citing papers by Mohammed Farooqui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammed Farooqui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed Farooqui. The network helps show where Mohammed Farooqui may publish in the future.

Co-authorship network of co-authors of Mohammed Farooqui

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammed Farooqui. A scholar is included among the top collaborators of Mohammed Farooqui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammed Farooqui. Mohammed Farooqui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study 2025 ·Blood ·(unknown), (unknown), (unknown), Constance M. Yuan, Hao‐Wei Wang, Inhye E. Ahn, Mohammed Farooqui, Xin Tian, Clare Sun, (unknown), Susan Soto, Jeanine Superata, (unknown), Thomas E. Hughes, Pia Nierman, Adrian Wiestner	0
2	Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study 2024 ·Leukemia & lymphoma ·Scott F. Huntington, Wendy Y. Cheng, Eric Sarpong, Siyang Leng, Mohammed Farooqui, (unknown), (unknown), Dominique Lejeune, (unknown), (unknown), Mei Sheng Duh, Enrico De Nigris	2
3	Wernicke's encephalopathy in an adolescent following bariatric surgery 2022 ·SHILAP Revista de lepidopterología ·Sathyaprasad Burjonrappa, Mohammed Farooqui, Yi‐Horng Lee	1
4	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study 2021 ·Blood Advances ·Gareth P. Gregory, Shaji Kumar, Ding Wang, Daruka Mahadevan, Patricia Walker, Nina D. Wagner‐Johnston, Carolina Escobar, Rajat Bannerji, Divaya Bhutani, Julie Chang, Francisco J. Hernandez‐Ilizaliturri, Andreas K. Klein, John M. Pagel, Witold B. Rybka, Andrew J. Yee, (unknown), Mo Huang, Mohammed Farooqui, Patricia Marinello, Hang Quach	24
5	Dual antibody immunohistochemistry: an efficient and sensitive tool for the detection of residual disease in chronic lymphocytic leukemia 2019 ·Journal of Hematopathology ·Laura Wake, Inhye E. Ahn, Mohammed Farooqui, Xin Tian, Maryalice Stetler‐Stevenson, Gerald E. Marti, Adrian Wiestner, Irina Marić	1
6	Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood 2017 ·Leukemia ·Thomas M. Herndon, (unknown), Nakhle S. Saba, Janet Valdez, Claire Emson, Michelle Gatmaitan, Xin Tian, Thomas E. Hughes, Clare Sun, D Arthur, Maryalice Stetler‐Stevenson, Christina M. Yuan, Carsten Utoft Niemann, Gerald E. Marti, Georg Aue, S. Soto, Mohammed Farooqui, Sarah E. M. Herman, Nicholas Chiorazzi, Adrian Wiestner	88
7	Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors 2017 ·Oncotarget ·Adam Albitar, Wanlong Ma, (unknown), (unknown), Inhye E. Ahn, Mohammed Farooqui, Adrian Wiestner, Maher Albitar	19
8	Utility of Indium-111 Octreotide to Identify a Cardiac Metastasis of a Carcinoid Neoplasm 2016 ·Baylor University Medical Center Proceedings ·Mohammed Farooqui, (unknown), (unknown)	4
9	Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib 2016 ·JAMA Oncology ·Clare Sun, Jin Gao, Laura Couzens, Xin Tian, Mohammed Farooqui, Maryna C. Eichelberger, Adrian Wiestner	63
10	Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo 2015 ·Clinical Cancer Research ·Sarah E. M. Herman, Rashida Z. Mustafa, Jade Jones, Deanna H. Wong, Mohammed Farooqui, Adrian Wiestner	91
11	Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study 2015 ·Clinical Cancer Research ·Carsten Utoft Niemann, Sarah E. M. Herman, Irina Marić, Julio Gómez‐Rodríguez, Angélique Biancotto, Betty Chang, Sabrina Martyr, Maryalice Stetler‐Stevenson, Constance M. Yuan, Katherine R. Calvo, Raul C. Braylan, Janet Valdez, Yuh Shan Lee, Deanna H. Wong, Jade Jones, Clare Sun, Gerald E. Marti, Mohammed Farooqui, Adrian Wiestner	160
12	Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy 2015 ·Clinical Cancer Research ·Martin Skarzynski, Carsten Utoft Niemann, Yuh Shan Lee, Sabrina Martyr, Irina Marić, Dalia Salem, Maryalice Stetler‐Stevenson, Gerald E. Marti, Katherine R. Calvo, Constance M. Yuan, Janet Valdez, Susan Soto, Mohammed Farooqui, Sarah E. M. Herman, Adrian Wiestner	62
13	Atrial Fibrillation in CLL/SLL Patients on Ibrutinib 2015 ·Blood ·Mohammed Farooqui, Janet Valdez, Susan Soto, Amanda Bray, Xin Tian, Adrian Wiestner	33
14	Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p 2013 ·Blood ·Mohammed Farooqui, Georg Aue, Janet Valdez, Sabrina Martyr, Jade Jones, Susan Soto, Maryalice Stetler‐Stevenson, Constance M. Yuan, Diane C. Arthur, Francine Thomas, Xin Tian, Delong Liu, Irina Marić, Adrian Wiestner	15
15	Automatic detection of axillary lymphadenopathy on CT scans of untreated chronic lymphocytic leukemia patients 2012 ·Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE ·Jiamin Liu, (unknown), (unknown), Nicholas Petrick, Berkman Sahiner, Mohammed Farooqui, Gerald E. Marti, Adrian Wiestner, Ronald M. Summers	3
16	Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1 2011 ·Leukemia & lymphoma ·Yair Herishanu, Federica Gibellini, Ndegwa Njuguna, Inbal Hazan‐Halevy, Mohammed Farooqui, (unknown), Keyvan Keyvanfar, Elinor Lee, Wyndham H. Wilson, Adrian Wiestner	93
17	Improved ZAP‐70 assay using two clones, multiple methods of analysis and clinical correlation 2011 ·Cytometry Part B Clinical Cytometry ·Heba Degheidy, David Venzon, Mohammed Farooqui, Fatima Abbasi, Diane C. Arthur, Wyndham H. Wilson, Adrian Wiestner, M Stetler-Stevenson, Gerald E. Marti	7
18	Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease 2011 ·British Journal of Haematology ·Santosh L. Saraf, Mohammed Farooqui, (unknown), (unknown), (unknown), Michel Gowhari, (unknown), Weihua Gao, (unknown), Donald Lavelle, Joseph DeSimone, Robert E. Molokie, Yogen Saunthararajah	5
19	Methodological comparison of two anti‐ZAP‐70 antibodies 2011 ·Cytometry Part B Clinical Cytometry ·Heba Degheidy, David Venzon, Mohammed Farooqui, Fatima Abbasi, Diane C. Arthur, Wyndham H. Wilson, Adrian Wiestner, M Stetler-Stevenson, Gerald E. Marti	6
20	Combined normal donor and CLL: Single tube ZAP‐70 analysis 2011 ·Cytometry Part B Clinical Cytometry ·Heba Degheidy, David Venzon, Mohammed Farooqui, Fatima Abbasi, Diane C. Arthur, Wyndham H. Wilson, Adrian Wiestner, M Stetler-Stevenson, Gerald E. Marti	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact